Personalis (NASDAQ:PSNL) Shares Gap Up – Should You Buy?

Personalis, Inc. (NASDAQ:PSNL)’s share price gapped up prior to trading on Wednesday . The stock had previously closed at $6.04, but opened at $6.82. Personalis shares last traded at $6.6670, with a volume of 1,246,028 shares trading hands.

Analyst Upgrades and Downgrades

PSNL has been the subject of a number of analyst reports. Morgan Stanley decreased their target price on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a research report on Tuesday. Guggenheim raised their target price on shares of Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st. BTIG Research decreased their target price on shares of Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Monday. Finally, Needham & Company LLC raised their target price on shares of Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $11.00.

Personalis Stock Performance

The business’s 50-day moving average price is $6.76 and its 200 day moving average price is $8.15. The company has a market cap of $699.53 million, a P/E ratio of -6.59 and a beta of 1.96.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. The firm had revenue of $15.47 million during the quarter, compared to the consensus estimate of $14.49 million. Equities research analysts forecast that Personalis, Inc. will post -1.01 earnings per share for the current year.

Institutional Trading of Personalis

Hedge funds have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Personalis by 76.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after buying an additional 1,479 shares during the period. Legal & General Group Plc bought a new stake in shares of Personalis during the 2nd quarter worth about $30,000. International Assets Investment Management LLC bought a new stake in shares of Personalis during the 4th quarter worth about $31,000. BNP Paribas Financial Markets boosted its holdings in shares of Personalis by 406.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after buying an additional 5,177 shares during the period. Finally, Focus Partners Wealth bought a new stake in shares of Personalis during the 1st quarter worth about $47,000. Institutional investors and hedge funds own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.